Department of Public Health, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
Int J Gynaecol Obstet. 2010 Dec;111(3):245-8. doi: 10.1016/j.ijgo.2010.07.008.
To assess, among women with HIV, whether long-term oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 supplementation can prevent bacterial vaginosis (BV) and enhance the cure rate of metronidazole among those with BV.
A randomized, double-blind, placebo-controlled trial conducted among 65 HIV-infected women with an aberrant microbiota (Nugent score 4-10) who were randomized to receive daily probiotics or placebo for 6 months. Those with BV (Nugent score 7-10) additionally received metronidazole for 10 days (400 mg twice daily).
We did not find an enhanced cure rate of BV among women with HIV treated with adjuvant probiotics to metronidazole treatment. Among women with an intermediate vaginal flora, probiotics tended to increase the probability of a normal vaginal flora (odds ratio 2.4; P=0.1) and significantly increased the probability of a beneficial vaginal pH (odds ratio 3.8; P=0.02) at follow-up.
Supplementation of probiotic L. rhamnosus GR-1 and L. reuteri RC-14 did not enhance the cure of BV among women living with HIV, but may prevent the condition among this population.
NCT00536848.
评估长期口服鼠李糖乳杆菌 GR-1 和罗伊氏乳杆菌 RC-14 补充剂是否可预防 HIV 感染者的细菌性阴道病 (BV)，并提高 BV 患者的甲硝唑治愈率。
一项随机、双盲、安慰剂对照试验，纳入了 65 名患有异常微生物群（Nugent 评分为 4-10）的 HIV 感染女性，这些女性被随机分为每日接受益生菌或安慰剂治疗 6 个月。BV（Nugent 评分为 7-10）患者另外接受甲硝唑治疗 10 天（400mg 每日 2 次）。
我们未发现辅助用益生菌治疗 HIV 女性的 BV 治愈率提高。对于阴道中间菌群的女性，益生菌治疗有增加正常阴道菌群的趋势（比值比 2.4；P=0.1），并且在随访时显著增加有益阴道 pH 值的概率（比值比 3.8；P=0.02）。
补充益生菌 L. rhamnosus GR-1 和 L. reuteri RC-14 并不能提高 HIV 感染者 BV 的治愈率，但可能预防该人群发生 BV。
NCT00536848。
